Karen Potts Email

SVP, Regulatory Affairs . MEI Pharma

Current Roles

Employees:
151
Revenue:
$33.3M
About
MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor that has been granted Breakthrough Therapy Designation from the FDA in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ?75 years of age or unfit for intensive chemotherapy. Our pipeline of drug candidates also includes ME-401 (formerly PWT143), a next-generation oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor. For more, please go to www.meipharma.com.
MEI Pharma Address
11455 El Camino Real
null, null
MEI Pharma Email

Past Companies

Solana Strategies ConsultingRegulatory Strategist
MEI PharmaSenior Vice President, Regulatory Affairs
Trius TherapeuticsSenior Vice President, Regulatory Affairs

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.